Skip to content
Accessibility help
Search NICE…
Skip to content
Menu
Sign in
Guidance
Standards and indicators
Life sciences
British National Formulary (BNF)
British National Formulary for Children (BNFC)
Clinical Knowledge Summaries (CKS)
About
Home
NICE guidance
In development
In development: Guidance, quality standards and advice
Skip to filters
Skip to results
Published
In consultation
In development
Awaiting development
Topic selection
Filter (1 applied)
Skip to results
Keyword or reference number
Keyword or reference number
Apply filter
Expected publication date
Expected publication date
From date
To date
Apply date filters
Area of interest
Area of interest
COVID-19 (3)
Type
(
1 selected
)
Type
Guidance (365)
NICE advice (1)
Quality standard (10)
Guidance programme
Guidance programme
Clinical guidelines (25)
Diagnostics guidance (5)
Health technology evaluations (14)
Highly specialised technologies guidance (7)
Interventional procedures guidance (19)
Medical technologies guidance (10)
NICE guidelines (29)
Public health guidelines (1)
Technology appraisal guidance (287)
Apply filters
Showing 31 to 40 of 365
Sort by
Title
Date
Apply sorting
Type: Guidance
Remove Type: Guidance filter
Guidance, NICE advice and quality standards in development
Title
Type
Expected publication date
Autologous chondrocyte implantation using 3D collagen matrix (novocart 3D) for treating articular cartilage defects of the knee [ID2707]
Technology appraisal guidance
TBC
Avelumab for previously treated platinum-resistant ovarian cancer ID1497
Technology appraisal guidance
TBC
Avelumab for untreated PD-L1 positive recurrent or metastatic non-small-cell lung cancer [ID1261]
Technology appraisal guidance
TBC
Avelumab with axitinib for untreated advanced renal cell carcinoma (MA review of TA645) [ID6294]
Technology appraisal guidance
25 June 2025
Beating heart mitral valve repair by artificial chordae insertion for mitral regurgitation
Interventional procedures guidance
4 March 2026
Bed frames for adults in medical or surgical hospital wards: Late Stage-assessment
Health technology evaluation
19 August 2025
Belantamab mafodotin for treating relapsed or refractory multiple myeloma after 4 or more therapies [ID2701]
Technology appraisal guidance
TBC
Belantamab mafodotin with bortezomib and dexamethasone for treating relapsed or refractory multiple myeloma after 1 or more treatments ID6212
Technology appraisal guidance
TBC
Belantamab mafodotin with pomalidomide and dexamethasone for treating relapsed or refractory multiple myeloma after 1 or more treatments ID6211
Technology appraisal guidance
TBC
Belzutifan for previously treated advanced renal cell carcinoma [ID6154]
Technology appraisal guidance
TBC
Previous page
1
2
3
Current page
4
5
6
…
37
Page
4
of
37
Next page
Results per page
10
25
50
All
Back to top